Truist Securities has revised its price target for Alnylam Pharmaceuticals downward to $410 per share, citing a tempered outlook for the company's ATTR amyloidosis franchise. The adjustment, announced on 18 July 2026, reflects growing caution among analysts about the competitive landscape and commercial trajectory of Alnylam's flagship therapy, vutrisiran, which targets transthyretin-mediated amyloidosis.
The price target cut comes as Alnylam navigates a shifting market for ATTR treatments, with rival drugs from competitors such as Pfizer and BridgeBio Pharma vying for market share. Truist's analysts noted that while vutrisiran remains a key growth driver, near-term revenue estimates may face headwinds from pricing pressures and slower-than-expected patient uptake in certain regions.
For UK investors and pension holders with exposure to biotech funds or US equities, the downgrade underscores the volatility inherent in the pharmaceutical sector. Alnylam's stock has fluctuated over the past year as clinical data and regulatory decisions have influenced sentiment. The FTSE 100-listed biotech peers, such as AstraZeneca, have also been affected by broader sector trends, though Alnylam's US listing means direct UK pension exposure is typically via global equity funds.
Analysts at Truist emphasised that Alnylam's long-term prospects remain tied to its broader pipeline, including RNAi therapeutics for other rare diseases. However, the near-term focus on ATTR has prompted a more conservative valuation. The new target of $410 represents a reduction from the previous level, though it still implies upside from current trading prices.
Market reaction on Friday saw Alnylam shares dip modestly in pre-market trading, reflecting investor caution. The biotech sector overall has been under pressure this year, with the Nasdaq Biotechnology Index down approximately 3% year-to-date as of mid-July, amid higher interest rates and regulatory scrutiny.